Given orphan drugs are intended to treat diseases that are very complex and diverse, development is often seen as a risk for the industry – requiring several years of research efforts in drug discovery with uncertainty for therapeutic outcomes.
By starting out with a complete clinical picture via multi-omic data, consisting of genomics, transcriptomics, proteomics, metabolomics, and phenomics data, we can now gain multilayer insights that help us develop better disease models and thus more precise medicine.
This session will focus on examples and emerging applications that demonstrate how multi-omic data can be leveraged to accelerate and de-risk rare disease drug discovery and development.
Carsten serves as the Senior Director of Artificial Intelligence, where he and his team apply AI solutions generate new insight about rare diseases from multiomics data and to improve the diagnoses processes. A metabolomics platform developed under his guidance recently won a German innovation award. Carsten is responsible for managing the company’s entire AI initiative, including evaluating the potential application of AI, identifying appropriate tools, and implementing solutions, as well as internal competency development and project portfolio expansion. Carsten holds the chair for Artificial Intelligence at Steinbeis University Berlin.
Research focuses on developing novel methods for leveraging heterogeneity present across independent cohorts to better understand human immune system for developing novel diagnostics and therapies for inflammatory diseases
Michael is the CEO of EB Research Partnership, an innovative medical research organization dedicated to curing the life-threatening genetic skin disease Epidermolysis Bullosa (EB) and leading the way for rare diseases with a pioneering venture investing and technology business model. Michael previously served as the Director of Development for the Multiple Myeloma Research Foundation leading their successful $100 million Curing Cancer Now campaign. Previously, Michael spent over a decade in leadership at the actor and philanthropist Paul Newman’s Hole in the Wall Gang Fund, working on behalf of children and their families battling cancer and other life-threatening illness. Michael received his MBA from Yale University, CORe credential from Harvard Business School, and an undergraduate degree in Philosophy from the University of Kansas.